Association of CRP and synovial fluid HMGB1 with Pain in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis: a cross-sectional study

This cross-sectional study demonstrates that in children with oligoarticular and polyarticular juvenile idiopathic arthritis, pain severity is independently associated with both systemic C-reactive protein levels and local synovial fluid markers of inflammation, particularly HMGB1.

The Gist

Imagine a child's body as a bustling city. In Juvenile Idiopathic Arthritis (JIA), a specific part of this city—the joints—gets into a state of constant, chaotic construction. There is inflammation, swelling, and damage happening inside the "buildings" (the joints).

For a long time, doctors have known that this construction causes pain. But here's the mystery: sometimes, even when the construction crew (treatment) is working hard to stop the inflammation, the pain doesn't go away. It's like the construction site is quiet, but the alarm system is still screaming.

This study asked a simple question: What is the specific "alarm signal" that keeps the pain screaming, even when the rest of the body seems calm?

The Two Types of Alarms

The researchers looked at two different places to find the answer:

1. The Bloodstream (The City's Main Highway): This represents the body's systemic (whole-body) state.
2. The Synovial Fluid (The Construction Site): This is the liquid inside the specific joint that hurts. It represents the local state.

They tested various "messengers" (biomarkers) in both places to see which ones were shouting the loudest when the child reported pain.

The Key Findings: The "Local Fire" vs. The "City Smoke"

The study discovered two main culprits responsible for the pain, but they play very different roles:

1. The Local Alarm: HMGB1 (The "Smoke Detector" inside the Joint)

• What it is: HMGB1 is a protein released when cells are stressed or damaged. Think of it as a smoke detector that goes off specifically inside the burning room (the joint).
• The Discovery: The study found that the higher the level of HMGB1 inside the joint fluid, the more pain the child felt.
• The Analogy: Imagine a house fire. Even if the smoke hasn't reached the street yet (the blood), the smoke detector inside the room is blaring. This study found that this "local blaring" (HMGB1) is a very strong predictor of pain. It suggests that the pain isn't just about the whole body being sick; it's about a specific, intense chemical signal happening right inside the hurting joint.

2. The Systemic Alarm: CRP (The "City-Wide Siren")

• What it is: C-Reactive Protein (CRP) is a standard marker doctors use to see if there is inflammation anywhere in the body. Think of it as a city-wide siren that goes off if there is a major fire anywhere in the city.
• The Discovery: When CRP levels were high in the blood, the children also reported more pain.
• The Catch: However, the study noted that many children had low CRP levels even when they were in pain. This means the "city siren" isn't always loud enough to tell the whole story. Sometimes the fire is contained to one room (the joint), so the city siren stays quiet, but the local smoke detector (HMGB1) is still screaming.

What Didn't Work?

The researchers also looked at other messengers like IL-6, IL-8, and markers of bone damage.

• The Analogy: They checked the weather forecast (cytokines) and the structural damage reports (bone markers). While these are important for understanding the disease, they didn't seem to correlate well with how much the child was hurting right now. It's like checking the weather report to predict a specific person's headache; it might be related, but it's not the direct cause.

Why This Matters (The "Aha!" Moment)

For years, doctors have treated JIA pain by trying to put out the "fire" (inflammation) using drugs. But this study suggests that pain is its own separate beast.

• The Old Way: "If we stop the inflammation, the pain will stop."
• The New Insight: "Even if we stop the big inflammation, a specific chemical (HMGB1) inside the joint might still be screaming 'PAIN!' to the brain."

The Takeaway

Think of the child's pain as a radio station.

• CRP is the signal coming from the main broadcast tower (the whole body).
• HMGB1 is a local transmitter right inside the joint.

This study tells us that to truly understand and treat the pain in children with JIA, we can't just listen to the main broadcast tower. We need to tune into the local transmitter.

In simple terms: To help these children feel better, we might need new medicines that specifically silence the "local smoke detector" (HMGB1) inside the joint, rather than just trying to calm down the whole body. This could lead to better pain relief for kids who aren't getting better with current treatments.

Technical Summary

Study Overview

Title: Association of CRP and synovial fluid HMGB1 with Pain in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis: a cross-sectional study
Authors: Xingzhao Wen et al.
Source: bioRxiv preprint (March 17, 2026)

1. Problem Statement

Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic condition in children, characterized by persistent joint inflammation, pain, and structural damage. Despite advances in anti-inflammatory treatments (e.g., methotrexate, biologics), pain remains a prevalent and distressing symptom for a significant proportion of patients, often persisting even when systemic inflammation is controlled.

• Knowledge Gap: The biological mechanisms driving persistent pain in JIA are not fully understood. While Damage-Associated Molecular Patterns (DAMPs) like High Mobility Group Box 1 (HMGB1) and S100A8/A9 are known to mediate inflammation and nociceptive sensitization, their specific associations with pain in JIA—particularly distinguishing between systemic (plasma) and local (synovial fluid) levels—have not been comprehensively characterized.
• Objective: To investigate the associations between a panel of inflammatory and tissue-derived biomarkers in plasma and synovial fluid (SF) and patient-reported pain scores in oligoarticular and polyarticular JIA.

2. Methodology

Study Design: Cross-sectional study utilizing a discovery-validation cohort approach.
Data Source: Samples and clinical data were retrieved from the Juvenile Arthritis Biobank (JABBA) at Astrid Lindgren's Children's Hospital, Stockholm.
Cohorts:

• Discovery Cohort: $n = 79$ patients (analyzed in a later experimental batch).
• Validation Cohort: $n = 38$ patients (analyzed in an earlier batch).
• Inclusion Criteria: Patients with oligoarticular or polyarticular JIA with paired plasma and synovial fluid (SF) samples. Only the earliest paired samples were used for patients with multiple visits.

Biomarkers Measured (via ELISA):

• DAMPs/Alarmins: HMGB1, S100A8/A9.
• Inflammatory Cytokines: IL-6, IL-8.
• Tissue Degradation Markers: C2C (cartilage degradation), TRAP5b (bone resorption).
• Systemic Marker: C-reactive protein (CRP).

Statistical Analysis:

• Preprocessing: Biomarker concentrations were log10-transformed to normalize distribution.
• Correlation: Spearman rank correlation assessed relationships between plasma/SF levels and between biomarkers and pain scores.
• Regression Modeling: Multivariable linear regression was used to assess associations between biomarkers and pain scores (dependent variable).
  • Adjustments: Models were adjusted for age, sex, disease duration, and treatment status (categorized into three levels).
• Sensitivity Analysis:
  • Pain was dichotomized into "low" and "high" groups based on the median.
  • LASSO (Least Absolute Shrinkage and Selection Operator) regression was used for variable selection to identify key predictors.
  • Multivariable logistic regression was performed on the selected variables.
• Validation: Findings from the discovery cohort were tested for reproducibility in the validation cohort using correlation and linear regression.

3. Key Results

A. Plasma vs. Synovial Fluid Correlation

• Most biomarkers (including HMGB1 and S100A8/A9) showed weak or no correlation between plasma and SF levels.
• Exception: TRAP5b showed a moderate positive correlation ($Rho = 0.55, p < 0.001$).
• Implication: Systemic levels do not reliably reflect local joint pathology in JIA.

B. Associations with Pain (Discovery Cohort)

• Unadjusted Analysis: Only Plasma CRP and SF HMGB1 showed significant positive associations with pain scores.
• Fully Adjusted Linear Regression:
  • Plasma CRP: Remained independently associated with higher pain ($\beta = 1.14, 95\% CI: 0.21–2.08$).
  • SF HMGB1: Showed the strongest independent association ($\beta = 1.54, 95\% CI: 0.06–3.01$).
  • SF S100A8/A9: Also associated with pain in the fully adjusted model ($\beta = 1.00, 95\% CI: 0.10–1.89$).
  • Other markers (IL-6, IL-8, C2C, TRAP5b) did not show significant independent associations.

C. Sensitivity Analysis (Logistic Regression)

• LASSO identified four predictors for high pain: Plasma CRP, SF HMGB1, Plasma S100A8/A9, and Plasma TRAP5b.
• In the final logistic model, Plasma CRP (OR 3.59) and SF HMGB1 (OR 4.61) were significantly associated with increased odds of being in the high-pain group.

D. Validation Cohort

• The associations were successfully replicated in the validation cohort ($n=38$).
• Significant positive correlations were found between Pain and Plasma CRP ($Rho=0.332$) and SF HMGB1 ($Rho=0.358$).
• Linear regression confirmed the robustness of these associations after adjusting for confounders.

4. Key Contributions

1. Local vs. Systemic Distinction: The study provides strong evidence that pain in JIA is driven by distinct mechanisms: systemic inflammation (reflected by CRP) and local joint-specific processes (reflected by SF HMGB1). It highlights that plasma levels of most biomarkers fail to capture local joint dynamics.
2. Identification of HMGB1 as a Key Mediator: SF HMGB1 is identified as a robust, treatment-independent biomarker associated with pain. This suggests HMGB1 acts not just as a marker of tissue damage but as an active driver of nociceptive sensitization in the joint.
3. Context-Dependent Role of S100A8/A9: While S100A8/A9 was associated with pain, the relationship appeared more sensitive to treatment status and confounders compared to HMGB1, suggesting a more complex or context-dependent role.
4. Methodological Rigor: The use of a discovery-validation design, combined with LASSO variable selection and multiple regression adjustments, strengthens the reliability of the findings despite the small sample size inherent to SF sampling in children.

5. Significance and Clinical Implications

• Pathophysiological Insight: The findings support the hypothesis that persistent pain in JIA is not solely a result of cumulative structural damage (as C2C and TRAP5b were not associated with pain) but is actively driven by inflammatory mediators and alarmins that sensitize nociceptors.
• Therapeutic Targets: HMGB1 emerges as a promising therapeutic target. Interventions targeting local joint-derived HMGB1 could potentially modulate both inflammation and pain, offering a strategy for patients who remain painful despite systemic anti-inflammatory control.
• Clinical Monitoring: The study suggests that assessing both systemic CRP and local SF HMGB1 (potentially via biomarker panels or future non-invasive proxies) could provide a more comprehensive understanding of pain mechanisms, aiding in the development of personalized pain management strategies for JIA patients.
• Limitations: The study is cross-sectional (limiting causal inference), relies on patient-reported pain (subject to psychosocial factors), and has a relatively small sample size due to the difficulty of obtaining SF from children. Longitudinal studies are recommended to confirm these findings.